{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T23:32:46Z","timestamp":1770247966095,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12517-1","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:36:39Z","timestamp":1767789399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic comorbidities, concomitant medications, and treatment patterns of chronic hepatitis B patients receiving nucleos(t)ide analogue therapy: a hospital claims database study in Japan"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9662-6997","authenticated-orcid":false,"given":"Daisuke","family":"Nakamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Ohata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Yuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Makino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotake","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nishizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohide","family":"Yokokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"12517_CR1","unstructured":"WHO Global hepatitis. report 2024: action for access in low- and middle-income countries, World Health Organization, Geneva2024. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240091672."},{"key":"12517_CR2","unstructured":"WHO Guidelines for the. diagnosis, care and treatment of persons with chronic hepatitis B infection. World Health Organization, Geneva 2024. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240090903."},{"issue":"Suppl 1","key":"12517_CR3","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/S0168-8278(03)00139-9","volume":"39","author":"G Fattovich","year":"2003","unstructured":"Fattovich G. Natural history of hepatitis B. J Hepatol. 2003;39(Suppl 1):S50\u20138.","journal-title":"J Hepatol"},{"key":"12517_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1472-6963-13-37","volume":"13","author":"J Lu","year":"2013","unstructured":"Lu J, Xu A, Wang J, Zhang L, Song L, Li R, et al. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. BMC Health Serv Res. 2013;13:37.","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"12517_CR5","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"GBDHB Collaborators","year":"2022","unstructured":"Collaborators GBDHB. Global, regional, and National burden of hepatitis B, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796\u2013829.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"12517_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.gtc.2020.01.001","volume":"49","author":"H Razavi","year":"2020","unstructured":"Razavi H. Global epidemiology of viral hepatitis. Gastroenterol Clin North Am. 2020;49(2):179\u201389.","journal-title":"Gastroenterol Clin North Am"},{"key":"12517_CR7","first-page":"100428","volume":"22","author":"J Tanaka","year":"2022","unstructured":"Tanaka J, Kurisu A, Ohara M, Ouoba S, Ohisa M, Sugiyama A, et al. Burden of chronic hepatitis B and C infections in 2015 and future trends in japan: A simulation study. Lancet Reg Health West Pac. 2022;22:100428.","journal-title":"Lancet Reg Health West Pac"},{"key":"12517_CR8","unstructured":"Infectious Agents Surveillance Report(IASR.) (No. 517). May 2023;44(3) Available from: https:\/\/www.niid.go.jp\/niid\/ja\/iasr-vol44\/11888-idx517.html."},{"issue":"1","key":"12517_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000515854","volume":"40","author":"H Yotsuyanagi","year":"2022","unstructured":"Yotsuyanagi H, Kurosaki M, Yatsuhashi H, Lee IH, Ng A, Brooks-Rooney C, et al. Characteristics and healthcare costs in the aging hepatitis B population of japan: A nationwide Real-World analysis. Dig Dis. 2022;40(1):68\u201377.","journal-title":"Dig Dis"},{"key":"12517_CR10","unstructured":"Government of Japan. Report on aging society. (2021), Available from: https:\/\/www8.cao.go.jp\/kourei\/english\/annualreport\/2021\/pdf\/2021.pdf, Accessed May 6, 2024."},{"key":"12517_CR11","unstructured":"Statistical, Bureau. Ministry of internal affairs and communications, Japan, Japan Statistical Yearbook 2024, Available from: https:\/\/www.stat.go.jp\/english\/data\/nenkan\/73nenkan\/index.html, Accessed May 6,2024."},{"key":"12517_CR12","doi-asserted-by":"crossref","unstructured":"Ishida T, Suzuki A, Nakata Y. Nationwide long-term evaluation of polypharmacy reduction policies focusing on older adults in Japan. Int J Environ Res Public Health. 2022;19(22).","DOI":"10.3390\/ijerph192214684"},{"issue":"8","key":"12517_CR13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/hepr.13504","volume":"50","author":"Drafting Committee for Hepatitis Management Guidelines tJSoH","year":"2020","unstructured":"Drafting Committee for Hepatitis Management Guidelines tJSoH. Japan society of hepatology guidelines for the management of hepatitis B virus infection: 2019 update. Hepatol Res. 2020;50(8):892\u2013923.","journal-title":"Hepatol Res"},{"issue":"20","key":"12517_CR14","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/cncr.29537","volume":"121","author":"WR Kim","year":"2015","unstructured":"Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, et al. Impact of long-term Tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015;121(20):3631\u20138.","journal-title":"Cancer"},{"issue":"8","key":"12517_CR15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1177\/135965350701200816","volume":"12","author":"MF Yuen","year":"2007","unstructured":"Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther. 2007;12(8):1295\u2013303.","journal-title":"Antivir Ther"},{"issue":"7","key":"12517_CR16","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41395-018-0093-9","volume":"113","author":"JW Shin","year":"2018","unstructured":"Shin JW, Jung SW, Lee SB, Lee BU, Park BR, Park EJ, et al. Medication nonadherence increases hepatocellular Carcinoma, cirrhotic Complications, and mortality in chronic hepatitis B patients treated with Entecavir. Am J Gastroenterol. 2018;113(7):998\u20131008.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"12517_CR17","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s40121-023-00795-0","volume":"12","author":"T Umemura","year":"2023","unstructured":"Umemura T, Wattanakamolkul K, Nakayama Y, Takahashi Y, Sbarigia U, KyungHwa L, et al. Real-World Epidemiology, clinical and economic burden of chronic hepatitis B in japan: A retrospective study using JMDC claims database. Infect Dis Ther. 2023;12(5):1337\u201349.","journal-title":"Infect Dis Ther"},{"key":"12517_CR18","unstructured":"MDV Database Overview. Available from: https:\/\/en.mdv.co.jp\/ebm\/about-mdv-database\/mdv-database-overview\/."},{"issue":"6","key":"12517_CR19","doi-asserted-by":"publisher","first-page":"e019985","DOI":"10.1136\/bmjopen-2017-019985","volume":"8","author":"DJ Ruzicka","year":"2018","unstructured":"Ruzicka DJ, Imai K, Takahashi K, Naito T. Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in japan: a cross-sectional study using a hospital claims database. BMJ Open. 2018;8(6):e019985.","journal-title":"BMJ Open"},{"issue":"25","key":"12517_CR20","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"key":"12517_CR21","doi-asserted-by":"crossref","unstructured":"Hudu SA, Shinkafi SH, Jimoh AO. A critical review of diagnostic and prognostic markers of chronic hepatitis B infection. Med Rev (2021). 2024;4(3):225\u2009\u2013\u200934.","DOI":"10.1515\/mr-2024-0022"},{"issue":"2","key":"12517_CR22","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/hep.30833","volume":"71","author":"GL Wong","year":"2020","unstructured":"Wong GL, Wong VW, Yuen BW, Tse YK, Luk HW, Yip TC, et al. An aging population of chronic hepatitis B with increasing comorbidities: A Territory-Wide study from 2000 to 2017. Hepatology. 2020;71(2):444\u201355.","journal-title":"Hepatology"},{"issue":"10","key":"12517_CR23","first-page":"1452","volume":"26","author":"YZ Yin","year":"2006","unstructured":"Yin YZ, Chen XW, Li XM, Hou HY, Shi ZJ. [Intrauterine HBV infection: risk factors and impact of HBV DNA]. Nan Fang Yi Ke Da Xue Xue Bao. 2006;26(10):1452\u20134.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"12517_CR24","doi-asserted-by":"publisher","first-page":"a2752","DOI":"10.1136\/bmj.a2752","volume":"338","author":"M Zhang","year":"2009","unstructured":"Zhang M, Holman CD, Price SD, Sanfilippo FM, Preen DB, Bulsara MK. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ. 2009;338:a2752.","journal-title":"BMJ"},{"key":"12517_CR25","doi-asserted-by":"publisher","first-page":"h949","DOI":"10.1136\/bmj.h949","volume":"350","author":"S Dumbreck","year":"2015","unstructured":"Dumbreck S, Flynn A, Nairn M, Wilson M, Treweek S, Mercer SW, et al. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK National clinical guidelines. BMJ. 2015;350:h949.","journal-title":"BMJ"},{"key":"12517_CR26","doi-asserted-by":"publisher","first-page":"101033","DOI":"10.1016\/j.pmedr.2019.101033","volume":"17","author":"S Mitsutake","year":"2020","unstructured":"Mitsutake S, Ishizaki T, Tsuchiya-Ito R, Teramoto C, Shimizu S, Yamaoka T, et al. Association of Pharmacological treatments for hypertension, diabetes, and dyslipidemia with health checkup participation and identification of disease control factors among older adults in Tokyo, Japan. Prev Med Rep. 2020;17:101033.","journal-title":"Prev Med Rep"},{"key":"12517_CR27","doi-asserted-by":"crossref","unstructured":"Songtanin B, Chaisrimaneepan N, Mendoza R, Nugent K. Burden, Outcome, and comorbidities of extrahepatic manifestations in hepatitis B virus infections. Viruses. 2024;16(4).","DOI":"10.3390\/v16040618"},{"issue":"2","key":"12517_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.14309\/ajg.0000000000001575","volume":"117","author":"P Cacoub","year":"2022","unstructured":"Cacoub P, Asselah T, Hepatitis B. Virus infection and Extra-Hepatic manifestations: A systemic disease. Am J Gastroenterol. 2022;117(2):253\u201363.","journal-title":"Am J Gastroenterol"},{"key":"12517_CR29","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2147\/CIA.S366255","volume":"17","author":"CK Kang","year":"2022","unstructured":"Kang CK, Brennan PN, Dillon JF. How to effectively monitor aging patients with chronic hepatitis B: A review. Clin Interv Aging. 2022;17:1811\u201320.","journal-title":"Clin Interv Aging"},{"key":"12517_CR30","doi-asserted-by":"publisher","first-page":"1176113","DOI":"10.3389\/fphys.2023.1176113","volume":"14","author":"J Xie","year":"2023","unstructured":"Xie J, Wang X, Pan D, Liu J, Li J, Gu J. Ageing and non-liver comorbidities in population with chronic hepatitis B infection in the Western Pacific region from 1990 to 2019. Front Physiol. 2023;14:1176113.","journal-title":"Front Physiol"},{"issue":"4","key":"12517_CR31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2478\/jtim-2024-0015","volume":"12","author":"J Wu","year":"2024","unstructured":"Wu J, Wang H, Xiang Z, Jiang C, Xu Y, Zhai G, et al. Role of viral hepatitis in pregnancy and its triggering mechanism. J Transl Int Med. 2024;12(4):344\u201354.","journal-title":"J Transl Int Med"},{"issue":"1","key":"12517_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2478\/jtim-2023-0010","volume":"11","author":"HJ Fu","year":"2023","unstructured":"Fu HJ, Zhou M, Huang ZH, Chen YX, Wu XX. Severe acute hepatitis of unknown origin in children: clinical issues of concern. J Transl Int Med. 2023;11(1):19\u201323.","journal-title":"J Transl Int Med"},{"issue":"4","key":"12517_CR33","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.3346\/jkms.2024.39.e22","volume":"39","author":"LY Kim","year":"2024","unstructured":"Kim LY, Yoo JJ, Chang Y, Jo H, Cho YY, Lee S, et al. The epidemiology of hepatitis B virus infection in korea: 15-Year analysis. J Korean Med Sci. 2024;39(4):e22.","journal-title":"J Korean Med Sci"},{"issue":"2","key":"12517_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3350\/cmh.2022.0084","volume":"28","author":"Korean Association for the Study of the L","year":"2022","unstructured":"Korean Association for the Study of the L. KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2022;28(2):276\u2013331.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"12517_CR35","doi-asserted-by":"publisher","first-page":"11435","DOI":"10.1038\/s41598-020-68021-2","volume":"10","author":"M Tatemichi","year":"2020","unstructured":"Tatemichi M, Furuya H, Nagahama S, Takaya N, Shida Y, Fukai K, et al. A nationwide cross-sectional survey on hepatitis B and C screening among workers in Japan. Sci Rep. 2020;10(1):11435.","journal-title":"Sci Rep"},{"issue":"6","key":"12517_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S2468-1253(24)00089-X","volume":"9","author":"PJ Easterbrook","year":"2024","unstructured":"Easterbrook PJ, Luhmann N, Bajis S, Min MS, Newman M, Lesi O, et al. WHO 2024 hepatitis B guidelines: an opportunity to transform care. Lancet Gastroenterol Hepatol. 2024;9(6):493\u20135.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"12517_CR37","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/apt.17107","volume":"56","author":"E Ogawa","year":"2022","unstructured":"Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, et al. Switching to Tenofovir Alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. Aliment Pharmacol Ther. 2022;56(4):713\u201322.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"12517_CR38","first-page":"12","volume":"14","author":"T Sano","year":"2021","unstructured":"Sano T, Amano K, Ide T, Kawaguchi T, Kuwahara R, Arinaga-Hino T, et al. Short-term efficacy after switching from Adefovir dipivoxil and Tenofovir disoproxil fumarate therapy to Tenofovir alaferamide for chronic hepatitis B. Biomed Rep. 2021;14(1):12.","journal-title":"Biomed Rep"},{"issue":"7","key":"12517_CR39","first-page":"601","volume":"18","author":"C Palleria","year":"2013","unstructured":"Palleria C, Di Paolo A, Giofre C, Caglioti C, Leuzzi G, Siniscalchi A, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci. 2013;18(7):601\u201310.","journal-title":"J Res Med Sci"},{"key":"12517_CR40","doi-asserted-by":"publisher","first-page":"923939","DOI":"10.3389\/fphar.2022.923939","volume":"13","author":"H Jiang","year":"2022","unstructured":"Jiang H, Lin Y, Ren W, Fang Z, Liu Y, Tan X, et al. Adverse drug reactions and correlations with drug-drug interactions: A retrospective study of reports from 2011 to 2020. Front Pharmacol. 2022;13:923939.","journal-title":"Front Pharmacol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12517-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12517-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12517-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T10:50:32Z","timestamp":1770202232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12517-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12517"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12517-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Juntendo University School of Medicine\u2019s IRB (Approval No. [E23-0338-M02]). Since the study used anonymized secondary data, the requirement for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Daisuke Nakamoto is employed by Gilead Sciences, Japan and Rie Kanamori is employed by Bristol Myers Squibb, Japan. However, Gilead Sciences and Bristol Myers Squibb Japan did not fund and were not involved in conducting this study. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}